RedHill Biopharma’s Phase 2/3 COVID-19 Study of Opaganib Passes Fourth DSMB Review with Unanimous Recommendation to Continue

Written by Petra Hegmann on 9th April 2021. Posted in Client News.

• Previous
• Next